FDA Orange Book · active-ingredient family
Vericiguat
Vericiguat is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:VERQUVO · NDA 214377
1
Brand (NDA)
0
Generics (ANDA)
6
Listed patents
6
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VERQUVORLD×3 | MSD | NDA 214377 | — | Jan 19, 2021 |
Marketing exclusivity (6)
- D-198New indication / change exclusivity (3 years)
Jan 21, 2029
in 2 yr 8 mo
- NCENew chemical entity exclusivity (5 years)
Jan 19, 2026
5 mo ago
- D-198New indication / change exclusivity (3 years)
Jan 21, 2029
in 2 yr 8 mo
- NCENew chemical entity exclusivity (5 years)
Jan 19, 2026
5 mo ago
- D-198New indication / change exclusivity (3 years)
Jan 21, 2029
in 2 yr 8 mo
- NCENew chemical entity exclusivity (5 years)
Jan 19, 2026
5 mo ago
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9993476 | May 19, 2031 | in 5 yr | U-3062 |
| 8921377 | May 19, 2031 | in 5 yr | U-3062 |
| 11439642 | May 19, 2031 | in 5 yr | U-3062 |
| 10736896 | May 19, 2031 | in 5 yr | SubstanceProduct |
| 8420656 | May 19, 2031 | in 5 yr | SubstanceProduct |
| 9604948 | Nov 26, 2032 | in 6 yr 6 mo | SubstanceProductU-3062 |
Vericiguat — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
